Division of Cardiovascular Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pa.
Pulmonary, Allergy, and Critical Care Division, University of Pennsylvania School of Medicine, Philadelphia, Pa.
J Thorac Cardiovasc Surg. 2017 May;153(5):1197-1203.e2. doi: 10.1016/j.jtcvs.2016.12.006. Epub 2016 Dec 15.
Donor blood transfusion has been identified as a potential risk factor for primary graft dysfunction and by extension early mortality. We sought to define the contributing risk of donor transfusion on early mortality for lung transplant.
Donor and recipient data were abstracted from the Organ Procurement and Transplantation Network database updated through June 30, 2014, which included 86,398 potential donors and 16,255 transplants. Using the United Network for Organ Sharing 4-level designation of transfusion (no blood, 1-5 units, 6-10 units, and >10 units, massive), we analyzed all-cause mortality at 30-days with the use of logistic regression adjusted for confounders (ischemic time, donor age, recipient diagnosis, lung allocation score and recipient age, and recipient body mass index). Secondary analyses assessed 90-day and 1-year mortality and hospital length of stay.
Of the 16,255 recipients transplanted, 8835 (54.35%) donors received at least one transfusion. Among those transfused, 1016 (6.25%) received a massive transfusion, defined as >10 units. Those donors with massive transfusion were most commonly young trauma patients. After adjustment for confounding variables, donor massive transfusion was associated significantly with an increased risk in 30-day (P = .03) and 90-day recipient mortality (P = .01) but not 1-year mortality (P = .09). There was no significant difference in recipient length of stay or hospital-free days with respect to donor transfusion.
Massive donor blood transfusion (>10 units) was associated with early recipient mortality after lung transplantation. Conversely, submassive donor transfusion was not associated with increased recipient mortality. The mechanism of increased early mortality in recipients of lungs from massively transfused donors is unclear and needs further study but is consistent with excess mortality seen with primary graft dysfunction in the first 90 days posttransplant.
供体输血已被确定为原发性移植物功能障碍的潜在危险因素,进而也是早期死亡的危险因素。我们试图确定供体输血对肺移植早期死亡率的影响。
从器官获取与移植网络数据库中提取供体和受体的数据,该数据库更新至 2014 年 6 月 30 日,包括 86398 名潜在供体和 16255 例移植。采用美国器官共享联合网络四级输血分类(无血、1-5 单位、6-10 单位和>10 单位,大量输血),使用 logistic 回归分析调整混杂因素(缺血时间、供体年龄、受体诊断、肺分配评分和受体年龄、受体体重指数)后,分析 30 天全因死亡率。次要分析评估 90 天和 1 年死亡率和住院时间。
在接受移植的 16255 例受体中,有 8835 例(54.35%)供体至少接受过一次输血。在输血的供体中,有 1016 例(6.25%)接受了大量输血,定义为>10 单位。大量输血的供体通常是年轻的创伤患者。在调整混杂变量后,供体大量输血与 30 天(P=0.03)和 90 天受体死亡率(P=0.01)显著相关,但与 1 年死亡率(P=0.09)无关。供体输血与受体住院时间或无住院天数无显著差异。
大量供体输血(>10 单位)与肺移植后受体早期死亡相关。相反,亚大量供体输血与受体死亡率增加无关。大量输血供体的受体早期死亡率增加的机制尚不清楚,需要进一步研究,但与移植后 90 天内原发性移植物功能障碍导致的死亡率增加一致。